Market brief — October 1, 2026

Hier, markets ended the session with a sharp rates-led cross-asset reset: the CAC 40 closed at 7,964.51 (-0.89%), the S&P 500 at 7,651.54 (-0.25%), the Nasdaq at 26,861.06 (+0.24%), the DAX at 25,199.19 (-0.79%), and the Euro Stoxx 50 at 6,269.02 (-0.81%). The dominant macro driver remains the Treasury selloff and the higher-for-longer term-premium shock, with Reuters reporting on October 1 that the U.S. 10-year yield hit 5.306%, its highest since mid-June 2007, while the 30-year reached 5.634% after touching 5.6517% in the prior session, the highest since 2002^[1][5]. The move looks less like a clean growth scare and more like a positioning unwind plus genuine macro repricing, because softer-than-expected U.S. inflation data reduced the odds of an October Fed hike, yet longer yields still pushed higher, suggesting duration supply, term premium and inflation-risk concerns are overwhelming the near-term policy relief^[1][2][5].

The key cross-asset signal is the divergence between easing front-end Fed-hike odds and still-rising long-end yields. Reuters said money markets cut the probability of an October hike to about 38%, down from 50% the day before, but the dollar still held near a two-month high as higher U.S. yields and persistent global price pressures supported it^[1][2]. That combination usually pressures broad equity multiples even when short-end rates ease, which explains why the Nasdaq can hold relatively better than Europe while the CAC 40 and DAX remain under pressure^[1][5]. For the next few sessions, that suggests the market is more likely to stay in a duration-sensitive, de-risking regime than to launch a clean risk-on rebound, unless long-end yields stabilize decisively.

The Cash Scanner is consistent with a selective, not broad, risk appetite. Leadership is concentrated in U.S. healthcare and software rather than in cyclicals: Warner Bros. Discovery (WBD) scored 41 with a breakout and ADX 40, PerkinElmer (RVTY) scored 39 with ADX 39, ImmunityBio (IBRX) scored 38 after a 6.9% gap higher, Twist Bioscience (TWST) scored 36 with a breakout and ADX 41, and NetApp (NTAP) scored 35 with a breakout and KST improvement. Doximity (DOCS) also screened well with a 6.9% gap and MACD/BB squeeze signals. The mix is notable: three life-sciences tools names, two biotech names, and two software names point to idiosyncratic momentum and earnings/technical follow-through, not a classic pro-cyclical rotation. That fits a market where investors are still willing to buy duration-equity proxies and high-quality growth, but only selectively and with strong technical confirmation.

Over the next 1–5 sessions, the dominant narrative is whether the long end can keep forcing equity valuation compression even as Fed-hike expectations soften. Consensus now expects the October Fed hike odds to keep falling after the softer inflation print, but what appears underappreciated is that the market may not need a hike to tighten financial conditions further if the 10-year stays above 5.25% and the 30-year remains near multi-decade highs^[1][2][5]. A credible contrarian scenario is that equities re-rate higher if yields finally stall on the back of weaker labor or growth data, but that would require confirmation that the bond move is peaking rather than merely pausing.

The immediate catalysts are the U.S. manufacturing PMI/ISM releases and jobless claims, which could either validate the “soft landing plus disinflation” camp or revive growth-stagflation fears^[12]. Also important are any follow-up comments from Fed officials after the softer inflation print, because the market is highly sensitive to whether policymakers lean against further tightening or keep optionality open^[1][11]. In Europe, the latest euro-area inflation pressure and the ECB’s cautious stance matter because a renewed energy-led upside surprise would keep bund yields elevated and reinforce the global duration selloff^[2][9]. In Asia, bond-market spillovers from Treasuries remain a risk, especially if Japanese and Australian yields continue to follow U.S. long-end weakness^[7][8].

Risks to monitor are straightforward but potent: first, another upside surprise in long-end Treasury yields above the recent 5.30% area, which would keep pressure on equities and the dollar^[1][5]; second, a further jump in euro-area inflation, which would invalidate any quick easing narrative in Europe^[2][9]; third, a negative liquidity impulse from month-end positioning and Treasury supply absorption, which could extend the duration unwind even without new macro shocks^[3][11].

If the 10-year yield holds above 5.25% and the 30-year stays near the 5.60% zone, Europe-sensitive equities and long-duration growth should remain vulnerable while selective U.S. software and healthcare momentum, such as NetApp, Doximity, and Twist Bioscience, can continue to outperform on stock-specific catalysts. If the 10-year slips back below the low-5.20% area and the dollar fades from its two-month high, the Nasdaq’s relative resilience versus the S&P 500 should broaden; if not, the current bounce risks staying narrow and tactical. For now, the CAC 40 and DAX remain the cleanest read on whether the rates shock is still dominating global equity positioning.

Bonne journée aux p&l makers.